Drugs Made In America Acquisition II Corp. (DMIIR) Key Statistics & Financial Ratios

Drugs Made In America Acquisition II Corp. (DMIIR) — Price $0.07 Financial ServicesFinancial - Conglomerates — NASDAQ

Latest reported results:

Key statistics dashboard for Drugs Made In America Acquisition II Corp. (DMIIR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Drugs Made In America Acquisition II Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company was founded on August 23, 2024 and is headquartered in Fort Lauderdale, FL.

Stock Data

Price$0.07
Market Cap$5M
Enterprise Value$4.9M
Beta4.70
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio0.33
Price / Book0.01
P/S0.00
EV/EBITDA-3.67
EV/Sales0.00
EV/FCF-5.09
P/FCF-4.80
Earnings Yield390.37%
FCF Yield-20.82%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity2.66%
Return on Assets2.53%
Return on Invested Capital-0.28%
Return on Capital Employed-0.28%

Financial Health

Current Ratio0.34
Quick Ratio0.34
Cash Ratio0.27
Debt / Equity0.00
Debt / Assets0.09%
Net Debt / EBITDA-0.21
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share9.92
Cash per share0.00
FCF per share-0.02
Tangible Book Value per share9.92
Dividend per share0.00

Explore sector: Financial Services · Financial - Conglomerates

More sections of DMIIR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks